Reslizumab for pediatric eosinophilic esophagitis

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pediatric eosinophilic esophagitis is an inflammatory condition associated with marked eosinophil accumulation in the mucosal tissues of the esophagus. Eosinophils are major proinflammatory cells thought to make a major contribution to allergic diseases that affect the upper and lower airways, skin and GI tract. IL-5 is central to eosinophil maturation and release from the bone marrow, and their subsequent accumulation, activation and persistence in the tissues. Reslizumab (Cinquil, Ception Therapeutics Inc., PA, USA) is a humanized monoclonal antibody with potent IL-5 neutralizing effects that represents a potential treatment for eosinophilic diseases. This article considers the current status of the clinical development of reslizumab for pediatric eosinophilic esophagitis.

Original languageEnglish
Pages (from-to)461-465
Number of pages5
JournalImmunotherapy
Volume2
Issue number4
DOIs
Publication statusPublished - Jul 2010

Keywords

  • Cinquil (TM)
  • eosinophils
  • IL-5
  • pediatric eosinophilic esophagitis
  • reslizumab
  • IL-5 receptor-alpha
  • human interleukin-5
  • Hypereosinophilic syndrome
  • decreased expression
  • asthma
  • hyperreactivity
  • Mepolizumab
  • antibody
  • gastroenteritis
  • aeroallergens

Fingerprint Dive into the research topics of 'Reslizumab for pediatric eosinophilic esophagitis'. Together they form a unique fingerprint.

  • Cite this